Advertisement
Canada markets close in 5 hours 2 minutes

  • S&P/TSX

    21,740.27
    -133.45 (-0.61%)
     

  • S&P 500

    4,999.00
    -72.63 (-1.43%)
     

  • DOW

    37,778.29
    -682.63 (-1.77%)
     

  • CAD/USD

    0.7296
    -0.0001 (-0.02%)
     

  • CRUDE OIL

    82.30
    -0.51 (-0.62%)
     

  • Bitcoin CAD

    86,677.82
    -2,420.09 (-2.72%)
     

  • CMC Crypto 200

    1,373.87
    -8.71 (-0.63%)
     

  • GOLD FUTURES

    2,354.70
    +16.30 (+0.70%)
     

  • RUSSELL 2000

    1,964.92
    -30.50 (-1.53%)
     

  • 10-Yr Bond

    4.7160
    +0.0640 (+1.37%)
     

  • NASDAQ

    15,421.46
    -291.28 (-1.85%)
     

  • VOLATILITY

    17.01
    +1.04 (+6.51%)
     

  • FTSE

    8,056.55
    +16.17 (+0.20%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6808
    -0.0011 (-0.16%)
     
BREAKING:

HONDA TO SET UP $15B EV PRODUCTION BASE IN CANADA

Automaker to get up to $5B in government assistance for EV battery, assembly plants

UPDATE 1-EU okays capacity increase at Moderna's U.S. sites

Reuters
·1 min read

(Adds details)

July 30 (Reuters) - The European drugs regulator on Friday approved a ramp-up in production of active substances used to make COVID-19 shots at Moderna's sites in the United States.

The European Medicines Agency (EMA) estimates the European market could get 40 million doses from Moderna's two approved U.S. facilities in the third quarter.

The agency said the approval reaffirms that the facilities - ModernaTX and Lonza Biologics - will help Moderna increase production capacity at the sites and will have a "significant" impact on the supply of the vaccine, known as Spikevax, in the EU.

EMA's human medicines committee has authorised a total of four manufacturing sites, two in the U.S. and two in Switzerland, for the production of active substances for the Moderna vaccine. (Reporting by Yadarisa Shabong in Bengaluru; Editing by Shailesh Kuber)